研究等業績 - その他 - 奥田 佑道
-
Yokota H.
Journal of Pharmaceutical Health Care and Sciences ( Journal of Pharmaceutical Health Care and Sciences ) 10 ( 1 ) 2024年12月
-
Sakamoto S.
Current Problems in Cancer: Case Reports ( Current Problems in Cancer: Case Reports ) 10 2023年06月
-
秋田県における新型コロナウイルス感染症の流行が高齢者の肺がん検診に与えた影響について
奥田 佑道, 浅野 真理子, 佐藤 一洋, 大本 瑛己, 坂本 祥, 竹田 正秀, 清水 辰徳, 大田 秀隆, 中山 勝敏
日本老年医学会雑誌 ( (一社)日本老年医学会 ) 60 ( Suppl. ) 182 - 182 2023年05月
-
Yokota H.
Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology ) 92 ( 4 ) 315 - 324 2023年
PURPOSE: Because of the large interindividual variability of afatinib pharmacokinetics and adverse events, we evaluated the effects of polymorphisms in pregnane X receptor (NR1I2) and ABC transporters (ABCB1, ABCG2, and ABCC2) on the pharmacokinetics of afatinib. METHODS: The steady-state area under the concentration-time curve (AUC)0-24 of afatinib was analyzed using blood sampling just prior to and at 1, 2, 4, 6, 8, 12, and 24 h on day 15 after administration. RESULTS: The median oral clearance (CL/F) of afatinib in patients with the NR1I2 7635A allele was significantly lower than those in patients with the 7635G/G genotype (42.0 and 60.0 L/h, respectively, P = 0.025). There were no significant differences in afatinib CL/F between genotypes for NR1I2 8055C > T, -25385C > T, ABCB1, ABCG2, and ABCC2 polymorphisms. Based on the area under the receiver-operating characteristic curve, the threshold afatinib AUC0-24 value for prediction of dose reduction or withdrawal was 689 ng·h/mL at the best sensitivity (81.0%) and specificity (72.7%). In multivariate logistic regression analysis, an afatinib AUC0-24 above 689 ng·h/mL was independently associated with increased risk of dose reduction or withdrawal (OR: 11.66, P = 0.012). CONCLUSIONS: The NR1I2 7635A allele was related to a lower afatinib CL/F. Based on the AUC of 689 ng h/mL and CL/F, the optimal doses for patients with the NR1I2 7635G/G genotype and 7635A allele were recommended to be set at 40 and 30 mg/day, respectively, and subsequent adjustment of the maintenance dose based on the plasma concentrations of afatinib may be necessary to avoid afatinib-related adverse events.
-
Yokota H.
Investigational New Drugs ( Investigational New Drugs ) 40 ( 6 ) 1254 - 1262 2022年12月
The effects of polymorphisms in CYP3A4 (20230G > A), CYP3A5 (6986A > G), ABCB1 (1236C > T, 2677G > T/A, 3435C > T), ABCG2 (421C > A), and ABCC2 (-24C > T) on the area under the concentration-time curve (AUC) of osimertinib in 23 patients with non-small cell lung cancer were investigated. Blood sampling was performed just prior to and at 1, 2, 4, 6, 8, 12, and 24 h after osimertinib administration at the steady-state on day 15 after beginning therapy. The osimertinib AUC0-24 was significantly correlated with age (P = 0.038), serum albumin (P = 0.002), and serum creatinine (P = 0.012). Additionally, there were significant differences in the AUC0-24 of osimertinib among the groups administered vonoprazan, histamine 2-receptor antagonists or esomeprazole, and no acid suppressants (P = 0.021). By contrast, there were no significant differences in the AUC0-24 of osimertinib between genotypes of CYP3A4/5 or ABC transporters. Furthermore, there were no significant differences in the AUC0-24 of osimertinib between patients with diarrhea, skin rash, or hepatotoxicity and those without these conditions. In multivariate analysis, only serum albumin value was an independent factor predicting the AUC0-24 of osimertinib. Analysis of CYP3A4/5 and ABC transporter polymorphisms before osimertinib therapy may not predict the efficacy or side effects of osimertinib. The lower serum albumin values were associated with an increase in the AUC0-24 of osimertinib; however, further studies are needed to assess the factors contributing to the interindividual variability of osimertinib pharmacokinetics.
-
オシメルチニブによる薬剤性肺障害が疑われた高齢者肺癌の1例
浅野 真理子, 佐藤 一洋, 坂本 祥, 奥田 佑道, 竹田 正秀, 佐野 正明, 横田 隼人, 三浦 昌朋, 大田 秀隆, 中山 勝敏
日本老年医学会雑誌 ( (一社)日本老年医学会 ) 59 ( 4 ) 575 - 575 2022年10月
-
高齢で診断された肺動静脈奇形を合併した遺伝性出血性末梢血管拡張症の1例
奥田 佑道, 佐藤 一洋, 五島 哲, 旭 ルリ子, 泉谷 有可, 坂本 祥, 浅野 真理子, 竹田 正秀, 大田 秀隆, 中山 勝敏
日本老年医学会雑誌 ( (一社)日本老年医学会 ) 59 ( 4 ) 576 - 576 2022年10月
-
Shimizu T.
Japanese Journal of Geriatrics ( Japanese Journal of Geriatrics ) 59 ( 4 ) 543 - 550 2022年
<p><b>目的：</b>認知症地域支援推進員の効率的な事業展開に向けて必要なことを検討する．<b>方法：</b>当センターがある秋田県において，25市町村の認知症地域支援推進員を対象に活動の現状を把握し，事業を効率的に展開するためにはどういったことが必要かを検討するための簡易アンケート調査を行った．<b>結果：</b>第一に認知症支援推進員の存在を地域住民に認知されていないことが判明し，その存在や活動を周知するような機会が必要であることが明らかになった．また推進員同士の情報共有や認知症の支援体制を構築するための社会資源を把握するツールなどが不足していることも明らかになった．また連携の面では，初期集中支援チームや疾患医療センターとの連携はとれているものの，認知症サポーターとの連携が不十分であることが判明した．さらに推進員の大きな役割である認知症ケアパスの作成や活動にはあまり関与しない実態が見えてきた．<b>結論：</b>今回の結果より，事業を効率的に展開するためのポイントとして，1．地域住民に対する認知症地域推進員を周知するための情報発信，2．認知症サポーターや民生委員との連携づくり，3．社会資源マップの作成やその把握，認知症ケアパスの有効活用，4．地域支援推進員が兼務しなくてよい労働環境の整備，5．認知症施策全体を理解するための学習の場づくり，の以上5点を提案する．</p>
-
当院における高齢者非小細胞肺癌に対するニボルマブの効果
奥田佑道, 浅野真理子, 佐藤一洋, 熊谷奈保, 坂本祥, 竹田正秀, 小玉鮎人, 大田秀隆, 中山勝敏
日本老年医学会雑誌 59 2022年
-
Yokota H.
Biology ( Biology ) 10 ( 10 ) 2021年10月
We evaluated the area under the plasma concentration-time curve (AUC) of afatinib required to avoid the onset of grade 2 or higher diarrhea. The C0 and AUC0-24 of afatinib were significant higher in patients with grade 2 diarrhea than in those with grade 0-1 diarrhea. The areas under the receiver operator curves were 0.795 with the highest sensitivity (89%) and specificity (74%) at an AUC0-24 threshold of 823.5 ng·h/mL, and 0.754 with the highest sensitivity (89%) and specificity (74%) at a C0 threshold of 28.5 ng/mL. In Kaplan-Meier analysis based on these cut-off AUC0-24 and C0 values, the median time to the incidence of grade 2 diarrhea was 16 days. The predicted AUC0-24 of afatinib from the single point of C6 showed the highest correlation with the measured AUC0-24 (r2 = 0.840); however, a significant correlation between the AUC0-24 and C0 was also observed (r2 = 0.761). C0 could be used as a marker of therapeutic drug monitoring because afatinib C0 was related to AUC0-24. Therefore, afatinib C0 should be monitored on day 8 after beginning therapy, and the daily dose of afatinib should be adjusted as an index with a cut-off value of 28.5 ng/mL.
-
Eosinophil extracellular traps in a patient with chronic eosinophilic pneumonia
Takeda M.
Asia Pacific Allergy ( Asia Pacific Allergy ) 11 ( 3 ) e24 2021年07月
Eosinophils rapidly release extracellular filamentous chromatin fibers (extracellular traps, ETs) when they are stimulated. Reticulated ETs have been recently shown to affect secretion viscosity in eosinophilic inflammatory diseases. Here we report a 43-year-old woman with infiltrative shadows in both upper lungs that did not respond well to antibiotics. She admitted to occasional coughing and sputum, but had poor viscous regulation. Bronchoalveolar lavage fluid (BALF) collected from the upper left lobe showed many eosinophils (65%). She was diagnosed with chronic eosinophilic pneumonia, per previously reported criteria, and began treatment with prednisolone. The infiltration shadow gradually improved, and she was discharged 28 days after admission. Later, we immune-stained her BALF cell components with antibodies against major basic protein, an eosinophil granule protein, which showed a large number of agglomerating eosinophils; and antibodies against citrullinated histone H3 (CitH3-a marker for ETs), which showed CitH3-positive ETs, spread in a network. These findings confirmed that some BALF eosinophils released eosinophil ETs. This case shows the existence of ETs from BALF in patients with chronic eosinophilic pneumonia. Concentration of eosinophil ETs in eosinophilic inflammatory diseases may affect secretion viscosity in sputum, and so on.
-
gefitinibの血中濃度と薬物動態に関する遺伝子多型との関係性についての検討
坂本 祥, 佐藤 一洋, 横田 隼人, 赤嶺 由美子, 奥田 佑道, 浅野 真理子, 竹田 正秀, 三浦 昌朋, 中山 勝敏
日本呼吸器学会誌 ( (一社)日本呼吸器学会 ) 10 ( 増刊 ) 208 - 208 2021年04月
-
Unusual morphologies of blood eosinophils in GM-CSF-producing lung cancer
Izumiya Y.
QJM : monthly journal of the Association of Physicians ( QJM : monthly journal of the Association of Physicians ) 114 ( 1 ) 42 - 44 2021年02月
-
Unusual morphologies of blood eosinophils in GM-CSF-producing lung cancer
Izumiya Y.
QJM ( QJM ) 114 ( 1 ) 42 - 44 2021年01月
-
Kodama A.
Japanese Journal of Geriatrics ( Japanese Journal of Geriatrics ) 58 ( 2 ) 266 - 271 2021年
<p>本研究の目的は，認知症初期集中支援チーム構成員を対象としたアンケート調査を実施し，秋田県内における認知症初期集中支援チームの活動動向を明らかにするとともに，今後の事業のさらなる効率的な推進に寄与すべく要因を明らかにすることである．県内の認知症初期集中支援チーム構成員46名を対象として，合計10項目からなるアンケート調査を実施した．その結果，認知症地域支援推進員や認知症疾患医療センターとの連携体制は概ね確立されているものの，居宅訪問を含めたかかりつけ医との連携が不十分であることが問題点として挙げられた．また，これまでも認知症初期集中支援チームにおける課題として取り上げられている認知症者の早期発見に対しては，この支援チームの存在を知ってもらうための地域住民に向けた周知・啓発や支援チームの介入のために本人ばかりでなく，ご家族との信頼関係の構築が重要であることが示唆された．</p>
-
EML4-ALK融合遺伝子陽性の高齢者肺癌の1例
奥田佑道, 奥田佑道, 佐藤一洋, 長谷川幸保, 滝田友里, 泉谷有可, 熊谷奈保, 浅野真理子, 浅野真理子, 竹田正秀, 大田秀隆, 中山勝敏
日本老年医学会雑誌 58 ( 4 ) 2021年
-
gefitinibの血中濃度と薬物動態に関する遺伝子多型との関係性についての検討
坂本祥, 佐藤一洋, 横田隼人, 赤嶺由美子, 奥田佑道, 浅野真理子, 竹田正秀, 三浦昌朋, 中山勝敏
日本呼吸器学会誌(Web) 10 2021年
-
Sakamoto S.
Investigational New Drugs ( Investigational New Drugs ) 38 ( 6 ) 1687 - 1695 2020年12月
ATP-binding castle protein G2 (ABCG2) is thought to inhibit the activities of certain gefitinib transporters, thereby affecting drug pharmacokinetics. The C421A polymorphism affects the function and expression of ABCG2 on the cell membrane. Previous studies have shown that proton-pump inhibitors (PPIs) inhibit gefitinib absorption, as well as the function of ABCG2. We evaluated the plasma concentrations of gefitinib in patients with and without the ABCG2 C421A polymorphism, who were or were not taking PPIs. In total, 61 patients with advanced epidermal-growth-factor-positive non-small-cell lung cancer were enrolled in this study. They were treated with gefitinib at a dose of 250 mg per day. Plasma gefitinib concentration and ABCG2 C421A status were determined after 2 weeks. The patients were divided into CC- and CA/AA genotype groups. We compared the trough and peak gefitinib levels and the area under the curve (AUC) values for 24-h gefitinib concentrations. We also compared these parameters among four groups distinguished according to the presence or absence of the polymorphism and PPI use. The mean trough gefitinib level and AUC value for 24-h gefitinib concentration were significantly lower in the CA/AA group compared to the CC group (mean trough level: 333.2 vs. 454.5 ng/mL, respectively, P = 0.021; AUC: 9949.9 vs. 13,085.4 ng・h/mL, respectively, P = 0.034). Among patients taking PPIs, the mean trough gefitinib level was significantly lower in the CA/AA group than the CC group (220.1 vs. 340.5 ng/mL, respectively, P = 0.033). The CA/AA-type of ABCG2 C421A polymorphism may be associated with lower gefitinib plasma concentrations.
-
熊谷 奈保, 滝田 友里, 泉谷 有可, 坂本 祥, 長谷川 幸保, 浅野 真理子, 奥田 佑道, 竹田 正秀, 佐野 正明, 佐藤 一洋, 中山 勝敏, 高嶋 祉之具, 今井 一博, 南谷 佳弘, 南條 博
肺癌 ( (NPO)日本肺癌学会 ) 60 ( 7 ) 1032 - 1032 2020年12月
-
胸壁原発Ewing肉腫の1例
熊谷 奈保, 滝田 友里, 泉谷 有可, 坂本 祥, 長谷川 幸保, 浅野 真理子, 奥田 佑道, 竹田 正秀, 佐野 正明, 佐藤 一洋, 中山 勝敏, 高嶋 祉之具, 今井 一博, 南谷 佳弘, 南條 博
肺癌 ( (NPO)日本肺癌学会 ) 60 ( 7 ) 1032 - 1032 2020年12月
-
Yokota H.
Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics ) 45 ( 4 ) 652 - 659 2020年08月
WHAT IS KNOWN AND OBJECTIVE: We investigated the correlations among signal transducer and activator of transcription 3 (STAT3) rs4796793C >G polymorphism, gefitinib pharmacokinetics and clinical responses in Japanese patients with non-small cell lung cancer receiving gefitinib therapy. METHODS: Forty-five patients were enrolled in this study. Plasma trough concentrations (C0 ) of gefitinib at the steady-state were measured by high-performance liquid chromatography. RESULTS AND DISCUSSION: Patients having a gefitinib C0 of at least ≥200 ng/mL had significantly longer PFS than patients having a C0 of <200 ng/mL (median [95% confidence interval (CI)] PFS: 11.0 [8.2-13.7] and 5.3 [0.0-12.0] months, respectively, P = .042). There were no significant differences in PFS between patients with STAT3 rs4796793C/C and G alleles; however, patients with STAT3 rs4796793C/C having a gefitinib C0 of ≥ 200 ng/mL had significantly longer progression-free survival (PFS) and overall survival (OS) than those with a C0 of <200 ng/mL (median [95% CI] PFS: 11.4 [4.1-18.6] and 3.0 [0.0-7.0] months, respectively, P = .008; median [95% CI] OS: 20.6 [7.4-33.7] and 12.6 [10.1-15.1] months, respectively, P = .042). In patients with the STAT3 rs4796793G allele, there were no significant differences in PFS and OS between the two gefitinib C0 groups. In addition, there were no significant differences in PFS or OS according to smoking, presence of proton pump inhibitor combination, or onset of side effects. WHAT IS NEW AND CONCLUSION: Clinical outcomes of gefitinib in patients with the STAT3 rs4796793C/C genotype depended on plasma concentrations of gefitinib. In addition to information regarding EGFR mutations, the STAT3 rs4796793C >G polymorphism and gefitinib C0 may be potential predictors of clinical outcomes after beginning of gefitinib therapy.
-
慢性好酸球性肺炎(CEP)患者のBALFに観察された好酸球ETosis
竹田 正秀, 坂本 祥, 佐藤 一洋, 植木 重治, 宮部 結, 佐野 正明, 奥田 佑道, 浅野 真理子, 長谷川 幸保, 熊谷 奈保, 廣川 誠, 中山 勝敏
日本呼吸器学会誌 ( (一社)日本呼吸器学会 ) 9 ( 増刊 ) 226 - 226 2020年08月
-
サルコイドーシス様の臨床像を呈したBCG膀胱内注入療法による播種性Mycobacterium bovis感染症の1例
長谷川幸保, 滝田友里, 泉谷有可, 熊谷奈保, 須藤和久, 坂本祥, 奥田佑道, 浅野真理子, 竹田正秀, 佐藤一洋, 中山勝敏, 三浦一樹
日本サルコイドーシス/肉芽腫性疾患学会雑誌 40 ( 1-2 ) 2020年
-
再検討で混合型小細胞癌と診断されたEGFR陽性肺腺癌の1例
滝田友里, 奥田佑道, 坂本祥, 泉谷有可, 熊谷奈保, 長谷川幸保, 浅野真理子, 竹田正秀, 佐野正明, 佐藤一洋, 中山勝敏, 廣嶋優子, 南條博
肺癌(Web) 60 ( 7 ) 2020年
-
再生検でALK遺伝子転座陽性となったEGFR遺伝子変異陽性肺腺癌の一例
奥田佑道, 佐藤一洋, 熊谷奈保, 坂本祥, 長谷川幸保, 浅野真理子, 竹田正秀, 中山勝敏
気管支学 42 2020年
-
慢性好酸球性肺炎(CEP)患者のBALFに観察された好酸球ETosis
竹田正秀, 坂本祥, 佐藤一洋, 植木重治, 宮部結, 佐野正明, 奥田佑道, 浅野真理子, 長谷川幸保, 熊谷奈保, 廣川誠, 中山勝敏
日本呼吸器学会誌(Web) 9 2020年
-
気管原発小細胞癌の一例
坂本祥, 坂本祥, 佐藤一洋, 旭ルリ子, 滝田友里, 泉谷有可, 長谷川幸保, 金田浩人, 浅野真理子, 奥田佑道, 竹田正秀, 杉山直幸, 中山勝敏
気管支学 42 2020年
-
胸壁原発Ewing肉腫の1例
熊谷奈保, 滝田友里, 泉谷有可, 坂本祥, 長谷川幸保, 浅野真理子, 奥田佑道, 竹田正秀, 佐野正明, 佐藤一洋, 中山勝敏, 高嶋祉之具, 今井一博, 南谷佳弘, 南條博
肺癌(Web) 60 ( 7 ) 2020年
-
Takeda M.
Journal of Medical Case Reports ( Journal of Medical Case Reports ) 13 ( 1 ) 118 - 118 2019年04月
BACKGROUND: Anaplastic lymphoma kinase-positive lung cancer is a form of lung cancer that accounts for approximately 5% of non-small cell lung cancers. Recently, anaplastic lymphoma kinase inhibitors have been used for treatment of anaplastic lymphoma kinase-positive lung cancer, and their high clinical effect has also been demonstrated in cases of advanced stage lung cancer. Alectinib is an anaplastic lymphoma kinase inhibitor that it is recognized as a standard drug for primary therapy because of its superiority to crizotinib. CASE PRESENTATION: A 37-year-old Japanese man was admitted to our hospital due to multiple brain metastases. An autopsy report revealed that the cause of death was anaplastic lymphoma kinase-positive lung cancer, exacerbated in a short period despite treatment with alectinib. Necropsy revealed anaplastic lymphoma kinase-positive adenosquamous carcinoma of the lung, suggesting that it was involved in the prognosis of this patient. Based on the autopsy results, we reviewed the pathological tissue from transbronchial lung biopsy at the time of clinical diagnosis. The tissue specimen for clinical diagnosis in this case was a papillary adenocarcinoma. However, when this tissue was immunostained, thyroid transcription factor 1-negative and cytokeratin 5/6-positive parts were recognized. This result indicates that we could diagnose this patient as having had adenosquamous carcinoma of the lung. CONCLUSION: In cases of anaplastic lymphoma kinase-positive lung cancer poorly responsive to anaplastic lymphoma kinase inhibitors, re-examination of the tissue should be considered because there is a possibility of anaplastic lymphoma kinase-positive adenosquamous carcinoma.
-
気道上皮細胞からのサイトカイン産生,粘液産生におけるPhosphoinositide 3-kinaseγの関わり
竹田 正秀, 佐藤 一洋, 植木 重治, 丹 典子, 泉谷 有可, 熊谷 奈保, 坂本 祥, 須藤 和久, 長谷川 幸保, 浅野 真理子, 奥田 佑道, 佐野 正明, 中山 勝敏
日本呼吸器学会誌 ( (一社)日本呼吸器学会 ) 8 ( 増刊 ) 250 - 250 2019年03月
-
Blepharoptosis due to sarcoidosis-induced horner syndrome
Takeda M.
American Journal of Respiratory and Critical Care Medicine ( American Journal of Respiratory and Critical Care Medicine ) 200 ( 1 ) 101 - 102 2019年
-
COPD・喘息における術後肺合併症のリスク因子の検討
中山勝敏, 沼田尊功, 浅野真理子, 奥田佑道, 荒屋潤, 板倉有紀, 大田秀隆, 桑野和善
日本老年医学会雑誌 56 2019年
-
gefitinibの薬物動態と血中濃度の変動に関する検討
中山勝敏, 坂本祥, 佐藤一洋, 奥田佑道, 浅野真理子, 板倉有紀, 大田秀隆, 横田隼人, 赤嶺由美子, 三浦昌朋
日本老年医学会雑誌 56 2019年
-
ゲフィチニブの治療効果におけるSTAT3遺伝子多型と体内曝露量の影響
横田隼人, 佐藤一洋, 坂本祥, 奥田佑道, 中山勝敏, 三浦昌朋
日本医療薬学会年会講演要旨集(Web) 29 2019年
-
化学療法継続のため血小板輸血に難渋した高齢者小細胞肺癌の1例
浅野真理子, 佐藤一洋, 熊谷奈保, 坂本祥, 須藤和久, 奥田佑道, 竹田正秀, 佐野正明, 大田秀隆, 中山勝敏
日本老年医学会雑誌 56 ( 4 ) 2019年
-
気道上皮細胞からのサイトカイン産生,粘液産生におけるPhosphoinositide 3-kinase γの関わり
竹田正秀, 佐藤一洋, 植木重治, 丹典子, 泉谷有可, 熊谷奈保, 坂本祥, 須藤和久, 長谷川幸保, 浅野真理子, 奥田佑道, 佐野正明, 中山勝敏
日本呼吸器学会誌(Web) 8 2019年
-
胸郭形成術後の呼吸機能障害に対しNPPVを長期使用した高齢患者の1例
奥田佑道, 佐藤一洋, 浅野真理子, 泉谷有可, 坂本祥, 須藤和久, 竹田正秀, 佐野正明, 大田秀隆, 中山勝敏
日本老年医学会雑誌 56 ( 4 ) 2019年
-
Validity of ultrasound lungcomets for assessment of the severity of interstitial pneumonia
Asano M.
Journal of Ultrasound in Medicine ( Journal of Ultrasound in Medicine ) 37 ( 6 ) 1523 - 1531 2018年06月
OBJECTIVES: Ultrasound (US) lung comets are often observed in patients with interstitial lung disease or congestive heart failure, but few studies have explored the clinical importance of US lung comets in patients with the former condition. We explored whether the US lung comet number could be used to assess the severity of interstitial pneumonia. METHODS: Forty stable patients with interstitial pneumonia were examined. Lung comets evident on transthoracic US imaging in 12 selected regions of the posterior chest wall were analyzed. We defined lung comets accompanied by thickened and irregular pleural lines as interstitial US lung comets; these predominated in patients with interstitial pneumonia. The total number of interstitial US lung comets was correlated with the data from chest high-resolution computed tomography, pulmonary function tests, serologic tests, and the 6-minute walk test. RESULTS: The 40 patients included 16 with idiopathic pulmonary fibrosis and 24 with nonspecific interstitial pneumonia. Thirty-four patients had interstitial US lung comets, which were more common in the lower than the upper lung area. Good correlations were evident between the lung comet number and the extent of the reticular pattern on chest high-resolution computed tomography (r = 0.710; P < .01), predicted forced vital capacity (r = -0.614; P < .01), and lung diffusion capacity for carbon monoxide (r = -0.577; P < .01). Notably, the lung comet number had a strong negative correlation with the percutaneous oxygen saturation level after the 6-minute walk test (r = -0.751; P < .01). CONCLUSIONS: The number of interstitial US lung comets evident on transthoracic US imaging may be a valuable marker of disease severity in patients with interstitial pneumonia.
-
びまん性の肺動静脈奇形に対し,経カテーテルコイル塞栓術を施行した4症例
奥田佑道, 佐藤一洋, 坂本祥, 須藤和久, 長谷川幸保, 浅野真理子, 竹田正秀, 飯野健二, 佐野正明, 塩谷隆信, 橋本学, 渡邊博之
秋田医学 44 ( 3/4 ) 2018年
-
中枢神経病変により多彩な症状をきたしたサルコイドーシスの一例
浅野真理子, 佐藤一洋, 竹田正秀, 奥田佑道, 須藤和久, 長谷川幸保, 坂本祥, 佐野正明, 渡邊博之
秋田医学 44 ( 3/4 ) 2018年
-
自己免疫性好中球減少症を合併したIgG4関連疾患の一例
坂本祥, 佐藤一洋, 熊谷奈保, 須藤和久, 浅野真理子, 奥田佑道, 竹田正秀, 佐野正明, 飯野健二, 渡邊博之, 塩谷隆信
日本サルコイドーシス/肉芽腫性疾患学会雑誌 38 ( 1-2 ) 2018年
-
遺伝性出血性末梢血管拡張症(HHT)患者における頭部MRI:SWI(Susceptibility-Weighted Imaging)を含めた検討
大谷隆浩, 高橋聡, 松田雅純, 浅野友之, 大高葵, 橋本学, 奥田佑道, 佐藤一洋, 佐野正明, 塩谷隆信
Japanese Journal of Radiology 36 ( Supplement ) 2018年
-
Yokota H.
Clinical Lung Cancer ( Clinical Lung Cancer ) 18 ( 6 ) e433 - e439 2017年11月
INTRODUCTION: In this study, we investigated the degree of drug interactions between gefitinib and gastric acid suppressants (ie, histamine 2-receptor antagonists [H2RAs] or proton pump inhibitors [PPIs]) with a clinical standard dose in Japanese patients with non-small-cell lung cancer. METHODS: Retrospectively, 47 patients were divided into 3 groups: gefitinib therapy with a PPI (15 patients) or an H2RA (8 patients) or gefitinib therapy alone (24 patients). On day 15 after beginning gefitinib therapy (administration at 08:00) with or without H2RA (administration twice daily at 08:00 and 18:30) or PPI (administration once daily at 08:00 or 18:30), whole blood samples were collected just prior to and at 1, 2, 4, 6, 8, 12, and 24 hours after administration. RESULTS: The total area under the observed plasma concentration-time curve (AUC0-24) and the maximum and trough plasma concentrations of gefitinib with the PPI were significantly lower than those without the PPI. The AUC0-24 of gefitinib with PPI administration in either the morning or evening were significantly lower than those without PPI administration (P = .015 and .049, respectively); however, there were no significant differences in gefitinib AUC0-24 between patients taking PPI in the morning and evening. No significant differences were observed in gefitinib exposure among the 3 CYP2C19 genotypes. The AUC0-24 of gefitinib with H2RA tended to be lower than that without H2RA. CONCLUSION: If the plasma concentrations of gefitinib cannot be monitored, the combination of gefitinib and PPI should be avoided, and an H2RA should also be used carefully.
-
Sudo K.
Anticancer Research ( Anticancer Research ) 37 ( 10 ) 5565 - 5571 2017年10月
-
Okuda Y.
Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology ) 79 ( 5 ) 1013 - 1020 2017年05月
PURPOSE: The relationship between the pharmacokinetics and effects of gefitinib in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is unknown. In this study, we examined the correlation between gefitinib plasma concentration and progression-free survival (PFS) in patients with two common types of EGFR mutations: a deletion in exon 19 and point mutations in exon 21 L858R. METHODS: The retrospective analysis examined 40 patients who were administered 250 mg of gefitinib daily. All patients were diagnosed with and treated for advanced non-small cell lung carcinoma with sensitive EGFR mutations between January 2011 and November 2013 at Akita University Hospital, Akita, Japan. The 40 patients were divided into four groups by trough plasma concentration (high or low) and mutation type (exon 19 deletions or exon 21 L858R point mutations). PFS, response rate, and toxic effects were analyzed in all four groups. RESULTS: After excluding 5 patients, the remaining 35 were successfully analyzed. For the patients with exon 19 deletions, there was no significant difference in PFS between the high and low plasma concentration groups (median survival: 12.0 vs. 17.0 months, P = 0.9548). In contrast, the PFS was significantly shorter for patients with exon 21 point mutations and low vs. high concentrations of gefitinib (median survival: 8.0 vs. 16.0 months, P < 0.05). CONCLUSIONS: The results suggest that low gefitinib plasma concentrations in patients with exon 21 L858R point mutations may be associated with shorter PFS in NSCLC patients.
-
呼吸不全に関する調査研究 日本における肺動静脈奇形の遺伝性出血性末梢血管拡張症(オスラー病)の合併の有無による比較
塩谷隆信, 佐竹將宏, 上村佐知子, 岩倉正浩, 浅野真理子, 奥田佑道, 守田亮, 三浦肇, 小高英達, 佐藤一洋, 佐野正明, 伊藤宏
呼吸不全に関する調査研究 平成28年度 総括研究報告書(Web) 2017年
-
胸壁浸潤した肺結核の1例
竹田正秀, 佐藤一洋, 奥田佑道, 浅野真理子, 坂本祥, 須藤和久, 長谷川幸保, 飯野健二, 佐野正明, 渡邊博之, 伊藤宏, 塩谷隆信
結核 92 ( 5 ) 2017年